MTNAP1

Summary

MTNAP1 (mitochondrial nucleoid associated protein 1, HGNC:29601) is a protein-coding gene on chromosome 17q25.1, encoding Mitochondrial nucleoid-associated protein 1 (Q9BSJ5). Critical regulator of mitochondrial DNA (mtDNA) abundance.

Predicted to be involved in cell population proliferation; mitochondrial DNA metabolic process; and positive regulation of mitochondrial DNA replication. Located in mitochondrial nucleoid.

Source: NCBI Gene 55028 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 11 total
• MANE Select transcript: NM_001351264

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29601
Approved symbol	MTNAP1
Name	mitochondrial nucleoid associated protein 1
Location	17q25.1
Locus type	gene with protein product
Status	Approved
Aliases	HLC-8, MIG3, FLJ20721, SPEP1
Ensembl gene	ENSG00000141219
Ensembl biotype	protein_coding
OMIM	620717
Entrez	55028

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 26 protein_coding

ENST00000255557, ENST00000268942, ENST00000359042, ENST00000426147, ENST00000535032, ENST00000577615, ENST00000582391, ENST00000582793, ENST00000585109, ENST00000893516, ENST00000893517, ENST00000893518, ENST00000893519, ENST00000934364, ENST00000934365, ENST00000934366, ENST00000934367, ENST00000934368, ENST00000934369, ENST00000934370, ENST00000934371, ENST00000953070, ENST00000953071, ENST00000953072, ENST00000953073, ENST00000953074

RefSeq mRNA: 9 — MANE Select: NM_001351264 NM_001100621, NM_001100622, NM_001288770, NM_001288771, NM_001351264, NM_001351265, NM_001386978, NM_001386979, NM_017941

CCDS: CCDS11694, CCDS42377, CCDS45767, CCDS74145

Canonical transcript exons

ENST00000535032 — 6 exons

Exon	Start	End
ENSE00001058278	73242896	73243003
ENSE00001265743	73233220	73233325
ENSE00001340095	73235476	73236995
ENSE00002714742	73247241	73248959
ENSE00003582896	73242244	73242351
ENSE00003918173	73232433	73232489

Expression profiles

Bgee: expression breadth ubiquitous, 258 present calls, max score 92.55.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.5770 / max 136.6362, expressed in 1704 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
162564	4.7595	1568
162566	2.8192	1274
162565	0.4829	266
162568	0.2933	136
162567	0.2222	99

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	92.55	gold quality
male germ cell	CL:0000015	89.92	gold quality
calcaneal tendon	UBERON:0003701	89.32	gold quality
left testis	UBERON:0004533	89.25	gold quality
right testis	UBERON:0004534	89.06	gold quality
testis	UBERON:0000473	88.25	gold quality
ganglionic eminence	UBERON:0004023	87.73	gold quality
biceps brachii	UBERON:0001507	87.35	gold quality
gastrocnemius	UBERON:0001388	87.31	gold quality
ventricular zone	UBERON:0003053	87.27	gold quality
muscle of leg	UBERON:0001383	87.24	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.88	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	86.81	gold quality
islet of Langerhans	UBERON:0000006	86.32	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.05	gold quality
hindlimb stylopod muscle	UBERON:0004252	86.02	gold quality
tendon	UBERON:0000043	85.65	gold quality
cortical plate	UBERON:0005343	84.15	gold quality
pigmented layer of retina	UBERON:0001782	84.05	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	84.02	gold quality
skeletal muscle organ	UBERON:0014892	83.67	gold quality
muscle organ	UBERON:0001630	83.65	gold quality
parotid gland	UBERON:0001831	83.25	silver quality
stromal cell of endometrium	CL:0002255	83.20	gold quality
cerebellar hemisphere	UBERON:0002245	82.57	gold quality
cerebellar cortex	UBERON:0002129	82.48	gold quality
middle temporal gyrus	UBERON:0002771	82.46	gold quality
adrenal tissue	UBERON:0018303	82.36	gold quality
apex of heart	UBERON:0002098	82.32	gold quality
muscle layer of sigmoid colon	UBERON:0035805	82.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.80

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

47 targeting MTNAP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-26A-1-3P	99.64	66.81	788
HSA-MIR-26A-2-3P	99.64	66.82	786
HSA-MIR-3685	99.62	68.83	1621
HSA-MIR-885-5P	99.59	68.59	879
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-4519	99.48	66.10	859
HSA-MIR-4687-3P	99.48	66.41	968
HSA-MIR-6740-3P	99.48	68.49	1392
HSA-MIR-501-3P	99.33	66.12	651
HSA-MIR-502-3P	99.33	66.12	651
HSA-MIR-6828-5P	99.31	69.21	1433
HSA-MIR-7974	99.24	65.48	1137
HSA-MIR-8077	99.17	66.67	862
HSA-MIR-6071	99.16	67.77	1780
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-548L	99.06	70.90	2560
HSA-MIR-9898	99.00	67.89	500
HSA-MIR-4709-3P	98.88	68.04	1594
HSA-MIR-501-5P	98.77	68.88	1328
HSA-MIR-6830-3P	98.62	68.07	1760
HSA-MIR-4274	98.59	66.10	630
HSA-MIR-1246	98.54	66.21	959

Literature-anchored findings (GeneRIF, showing 2)

• Uncharacterized protein C17orf80 - a novel interactor of human mitochondrial nucleoids. (PMID:37401363)
• C17orf80 binds the mitochondrial genome to promote its replication. (PMID:37676315)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mtnap1	ENSMUSG00000041623
rattus_norvegicus	Mtnap1	ENSRNOG00000024780

Protein

Protein identifiers

Mitochondrial nucleoid-associated protein 1 — Q9BSJ5 (reviewed: Q9BSJ5)

Alternative names: Cell migration-inducing gene 3 protein, Human lung cancer oncogene 8 protein, Protein C17orf80

All UniProt accessions (5): Q9BSJ5, I3L072, J3KT60, J3KTJ7, J3QLV1

UniProt curated annotations — full annotation on UniProt →

Function. Critical regulator of mitochondrial DNA (mtDNA) abundance. Binds dsDNA throughout the mitochondrial genome without sequence specificity and controls mtDNA copy number by promoting its replication. Also plays important roles in mitochondrial metabolism and cell proliferation.

Subcellular location. Mitochondrion inner membrane. Mitochondrion matrix. Mitochondrion nucleoid.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9BSJ5-1	1	yes
Q9BSJ5-2	2
Q9BSJ5-3	3

RefSeq proteins (9): NP_001094091, NP_001094092, NP_001275699, NP_001275700, NP_001338193, NP_001338194, NP_001373907, NP_001373908, NP_060411 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR037694	MTNAP1	Family

UniProt features (22 total): sequence variant 7, splice variant 3, sequence conflict 3, region of interest 3, topological domain 2, compositionally biased region 2, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BSJ5-F1	44.70	0.03

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 95 (showing top): RNGTGGGC_UNKNOWN, MODULE_205, GOCC_MITOCHONDRIAL_ENVELOPE, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GOCC_NUCLEOID, GOCC_MITOCHONDRIAL_MATRIX, GOCC_ORGANELLE_INNER_MEMBRANE, SCGGAAGY_ELK1_02, MANALO_HYPOXIA_DN, GOCC_ORGANELLE_ENVELOPE, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A, VANOEVELEN_MYOGENESIS_SIN3A_TARGETS, KUMAR_PATHOGEN_LOAD_BY_MACROPHAGES, ZWANG_DOWN_BY_2ND_EGF_PULSE, KRAS.600.LUNG.BREAST_UP.V1_DN

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), mitochondrial nucleoid (GO:0042645), extracellular exosome (GO:0070062), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
mitochondrion	1
mitochondrial matrix	1
nucleoid	1
intracellular membraneless organelle	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1356 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MTNAP1	VPS4B	O75351	583
MTNAP1	PRY	O14603	445
MTNAP1	VCF1	Q969W3	400
MTNAP1	PLAC1	Q9HBJ0	400
MTNAP1	ZNF534	Q76KX8	399
MTNAP1	GAB4	Q2WGN9	392
MTNAP1	BSPH1	Q075Z2	390
MTNAP1	SPATA31D1	Q6ZQQ2	390
MTNAP1	ZBED5	Q49AG3	368
MTNAP1	TMEM185B	Q9H7F4	353
MTNAP1	BLTP3B	A0JNW5	337
MTNAP1	GRAMD2A	Q8IUY3	323
MTNAP1	HHATL	Q9HCP6	316
MTNAP1	ATP5PD	O75947	303
MTNAP1	ATP5PF	P18859	300

IntAct

74 interactions, top by confidence:

A	B	Type	Score
CAMKV	AP3B1	psi-mi:“MI:0914”(association)	0.640
SLC39A5	FAM171A2	psi-mi:“MI:0914”(association)	0.640
MTNAP1	FLNA	psi-mi:“MI:0915”(physical association)	0.560
MYG1	MTNAP1	psi-mi:“MI:0915”(physical association)	0.560
PIAS4	MTNAP1	psi-mi:“MI:0915”(physical association)	0.560
PDPK1	AGRN	psi-mi:“MI:0914”(association)	0.530
TOR1AIP2	TMEM223	psi-mi:“MI:0914”(association)	0.530
HLA-DPA1	TYW5	psi-mi:“MI:0914”(association)	0.530
IL13RA2	METTL15	psi-mi:“MI:0914”(association)	0.530
HADHA	AGRN	psi-mi:“MI:0914”(association)	0.530
YBEY	NME4	psi-mi:“MI:0914”(association)	0.530
LRP1	NME4	psi-mi:“MI:0914”(association)	0.530
HADHB	POTEI	psi-mi:“MI:0914”(association)	0.530
HADHA	GPC4	psi-mi:“MI:0914”(association)	0.530
CCT8L2	ACSL4	psi-mi:“MI:0914”(association)	0.530
HSPA1B	MTNAP1	psi-mi:“MI:0915”(physical association)	0.400
SIRT4	VWA8	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
CAPZB	ENAH	psi-mi:“MI:0914”(association)	0.350
FARP1	SDC3	psi-mi:“MI:0914”(association)	0.350
H2BC21	SMCHD1	psi-mi:“MI:0914”(association)	0.350
PSPC1	MCRIP1	psi-mi:“MI:0914”(association)	0.350
SRP9	RPS3A	psi-mi:“MI:0914”(association)	0.350

BioGRID (310): C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), KCNA5 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS), C17orf80 (Affinity Capture-MS)

ESM2 similar proteins: A2ADZ8, A6NNH2, D2J0Y4, D3YU32, P0C2Y1, Q0VET5, Q12802, Q14676, Q149B8, Q283Q6, Q2TBI7, Q3KR64, Q3U0P1, Q4KMZ1, Q4R736, Q5QJ38, Q5R5G4, Q5T1N1, Q5TM68, Q5VWK0, Q5VYM1, Q5ZK13, Q68A65, Q6AZ54, Q6NXZ1, Q6PG16, Q6PIX9, Q7YR40, Q7Z572, Q86Y26, Q8BHP2, Q8BHW6, Q8C0D9, Q8C5V8, Q8C9M2, Q8CGM2, Q8N5Q1, Q8NCD3, Q8WP21, Q924C5

Diamond homologs: Q5R5G4, Q6PIX9, Q9BSJ5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 96 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Attachment and Entry	5	43.5×	7e-06
Defective B4GALT7 causes EDS, progeroid type	5	41.4×	7e-06
Defective B3GAT3 causes JDSSDHD	5	41.4×	7e-06
Defective B3GALT6 causes EDSP2 and SEMDJL1	5	41.4×	7e-06
HS-GAG degradation	5	36.0×	1e-05
Respiratory syncytial virus (RSV) attachment and entry	5	36.0×	1e-05
Initiation of coagulation cascade	5	34.5×	1e-05
Glycosaminoglycan-protein linkage region biosynthesis	5	28.5×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

11 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	5
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

921 predictions. Top by Δscore:

Variant	Effect	Δscore
17:73242889:T:TA	acceptor_gain	1.0000
17:73242893:CA:C	acceptor_loss	1.0000
17:73242894:A:AG	acceptor_gain	1.0000
17:73242894:AG:A	acceptor_gain	1.0000
17:73242894:AGGCT:A	acceptor_gain	1.0000
17:73242895:G:GG	acceptor_gain	1.0000
17:73242895:GG:G	acceptor_gain	1.0000
17:73242895:GGCT:G	acceptor_gain	1.0000
17:73242895:GGCTG:G	acceptor_gain	1.0000
17:73242999:TCTGA:T	donor_gain	1.0000
17:73243000:CTGAG:C	donor_loss	1.0000
17:73243001:TGAGT:T	donor_loss	1.0000
17:73243002:GA:G	donor_gain	1.0000
17:73243003:AGT:A	donor_loss	1.0000
17:73243004:G:A	donor_loss	1.0000
17:73243004:G:GG	donor_gain	1.0000
17:73243005:T:A	donor_loss	1.0000
17:73233154:A:AG	acceptor_gain	0.9900
17:73233155:G:GG	acceptor_gain	0.9900
17:73233247:A:AG	acceptor_gain	0.9900
17:73233247:ACTC:A	acceptor_gain	0.9900
17:73233247:ACTCG:A	acceptor_gain	0.9900
17:73233323:CGGG:C	donor_loss	0.9900
17:73233324:GG:G	donor_gain	0.9900
17:73233324:GGGTA:G	donor_loss	0.9900
17:73233325:GG:G	donor_gain	0.9900
17:73233326:G:GA	donor_loss	0.9900
17:73233327:T:A	donor_loss	0.9900
17:73242242:A:AG	acceptor_gain	0.9900
17:73242243:G:GG	acceptor_gain	0.9900

AlphaMissense

3981 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:73235534:T:C	F18L	0.984
17:73235536:T:A	F18L	0.984
17:73235536:T:G	F18L	0.984
17:73235513:T:C	C11R	0.982
17:73235554:C:A	H24Q	0.973
17:73235554:C:G	H24Q	0.973
17:73235544:T:C	L21S	0.972
17:73235539:A:C	K19N	0.969
17:73235539:A:T	K19N	0.969
17:73236872:T:A	W464R	0.968
17:73236872:T:C	W464R	0.968
17:73235564:T:A	C28S	0.966
17:73235565:G:C	C28S	0.966
17:73235515:T:G	C11W	0.965
17:73235548:A:C	K22N	0.965
17:73235548:A:T	K22N	0.965
17:73235552:C:G	H24D	0.964
17:73235513:T:A	C11S	0.963
17:73235514:G:C	C11S	0.963
17:73235565:G:A	C28Y	0.959
17:73235566:T:G	C28W	0.955
17:73235564:T:C	C28R	0.952
17:73235522:T:A	C14S	0.950
17:73235523:G:C	C14S	0.950
17:73236875:T:C	F465L	0.950
17:73236877:T:A	F465L	0.950
17:73236877:T:G	F465L	0.950
17:73235524:T:G	C14W	0.948
17:73235541:G:C	R20P	0.948
17:73235535:T:C	F18S	0.947

dbSNP variants (sampled 300 via entrez): RS1000011998 (17:73239086 G>A), RS1000087812 (17:73244762 C>T), RS1000147716 (17:73245599 G>A), RS1000524839 (17:73244982 G>A), RS1000532584 (17:73241319 G>A,T), RS1000647135 (17:73241455 G>A), RS1000647397 (17:73240020 T>A), RS1000902746 (17:73234519 C>A,T), RS1000929382 (17:73231396 C>T), RS1001129809 (17:73246467 C>T), RS1001200119 (17:73238347 G>T), RS1001235126 (17:73234254 A>G), RS1001312504 (17:73244179 A>G), RS1001497537 (17:73246263 G>A), RS1001615001 (17:73245247 G>A,T)

Disease associations

OMIM: gene MIM:620717 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90002385_318	High light scatter reticulocyte count	6.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007986	reticulocyte count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	3
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
methylmercuric chloride	decreases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Air Pollutants	increases abundance, affects expression	1
Air Pollutants, Occupational	decreases expression	1
Caffeine	increases phosphorylation	1
Cisplatin	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Lead	affects expression	1
Methotrexate	increases expression	1
Methyl Methanesulfonate	increases expression	1
Nickel	decreases expression	1
Oxygen	decreases expression	1
Ozone	affects expression, increases abundance	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Metribolone	increases expression	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B5JM	HAP1 C17orf80 (-) 2	Cancer cell line	Male
CVCL_B5JN	HAP1 C17orf80 (-) 3	Cancer cell line	Male
CVCL_B5JP	HAP1 C17orf80 (-) 4	Cancer cell line	Male
CVCL_B5JQ	HAP1 C17orf80 (-) 5	Cancer cell line	Male
CVCL_XM26	HAP1 C17orf80 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer